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PULMONARY HYPERTENSION IN ADOLESCENTS WITH SICKLE CELL 
DISEASE 
 
KATHERINE AKINYEMI 
 
ABSTRACT 	 Sickle cell disease consists of a group of disorders that have a similar 
mutation in at least one of the beta-globin chains of hemoglobin. This results in a 
change of the hemoglobin to sickle shaped cells when in the deoxygenated state. 
It is these sickled cells that lead to the symptoms and complications 
characteristic of sickle cell disease, including vaso-occlusion. The recurrence of 
sickling and polymerization in the blood vessels throughout the body ultimately 
results in tissue and organ damage that increases the mortality of patients. 
 Pulmonary hypertension is the increase in blood pressure in the 
pulmonary vasculature causing less blood to reach the lungs. The right side of 
the heart has to pump harder to compensate for this, which can ultimately lead to 
right heart failure. With vaso-occlusion being the major complication in sickle cell 
disease and affecting many tissues and organs like the lungs, pulmonary 
hypertension has become a major risk factor in these patients, especially in 
children. Most research has been with adults so the seriousness of this condition 
is still being discovered in children. 
		 v 
This review will cover the important aspects of both sickle cell disease and 
pulmonary hypertension then discuss how pulmonary hypertension has become 
a significant risk factor for death in those with sickle cell disease. From there the 
importance of this finding in children will be discussed and a plan for future 
endeavors will be proposed. 
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SICKLE CELL DISEASE 	
What is Sickle Cell Disease? 
Sickle cell disease (SCD) refers to a group of disorders with autosomal 
recessive inheritance that are caused by abnormal hemoglobin (Genetics, 2002). 
Hemoglobin contains two alpha-globin subunits and two beta-globin subunits and 
along with heme it forms the adult form of this protein in red blood cells that 
transports oxygen from the lungs to the tissues of the body (Benson & Therrell Jr, 
2010).  
 
History 
 Dr. James Herrick first described the abnormal red blood cells of SCD in 
1910. He studied the blood of a young man who was at a school in Chicago but 
was originally from Grenada, West Indies. Since little to no information was 
known about this condition yet Herrick was only able to give his details of the 
sickled cells shape without a diagnosis of the disorder causing them (Herrick, 
2001). 
 In 1915 Dr. Victor Emmel studied the blood of a patient with sickle cell 
anemia by making blood preparations on slides sealed with petrolatum. He 
observed the transformation of his patient’s normal red blood cells into the 
sickled cells characteristic of SCD. He also looked at the blood of his patient’s 
healthy father and noticed that the father’s blood also sickled but not to the same 
	 2	
extent as his patient, making this Emmel’s first attempt to determine a form of 
inheritance (EMMEL VE, 1917). 
 Decades later in 1949 Dr. James Neel looked at patients with sickle cell 
anemia and their parents. This allowed him to differentiate between the 
heterozygous sickle cell trait population, consisting of those carrying the sickle 
gene but not manifesting any symptoms, and the homozygous sickle cell anemia 
trait, consisting of those who had the actual disorder (Neel, 1949). 
 That same year Linus Pauling used gel electrophoresis to compare the 
hemoglobin of normal individuals, sickle cell anemia individuals, and sickle cell 
trait individuals. He observed that they all had different migratory patterns with 
the normal hemoglobin moving as a negative ion, the sickle cell anemia 
hemoglobin moving as a positive ion, and the sickle cell trait hemoglobin being a 
mixture of both the normal and sickle cell anemic patterns. This caused Pauling 
to suggest that there was a difference in the ionizable groups in the two 
hemoglobin’s and he hypothesized that the two conditions had different globins 
(Pauling, Itano, Singer, & Wells, 1949). 
 In 1957 Dr. Vernon Ingram compared the hemoglobin of normal 
individuals to those with sickle cell anemia using trypsin to digest the 2 proteins 
into peptides then using electrophoresis and chromatography to separate the 
peptides on paper. He noticed that there was a difference in only one peptide of 
the two hemoglobin’s which lead him to discover that sickle cell hemoglobin was 
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caused by a single amino acid substitution of the normal hemoglobin (Hunt & 
Ingram, 1960). 
 
Molecular Pathogenesis 
In SCD the abnormal hemoglobin results from a mutation in the beta-
globin gene which is located on chromosome 11 (Fonseca, Souza, Salemi, 
Jardim, & Gualandro, 2012). In this point mutation there is a nucleotide change 
from thymine to adenine causing the sixth amino acid of the beta-globin chain, 
which was originally glutamic acid, to be replaced with valine. This new protein is 
now known as hemoglobin S (HbS). The replacement of the polar glutamic acid 
side chain with the non-polar valine side chain causes hydrophobic interactions 
between the beta subunits of adjacent hemoglobin molecules when they are in 
the deoxygenated state. These hydrophobic interactions cause polymerization of 
the HbS molecules which then cluster together in the red blood cells resulting in 
their distortion from normal biconcave discs to misshapen sickled cells (Figure 1) 
(Bunn, 1997). This sickling causes the red blood cells to lose their structural 
integrity and impedes blood flow through the vessels eventually leading to tissue 
and organ injury and resulting in the symptoms and complications associated 
with SCD (Caboot & Allen, 2013). 
	 4	
 
 
Figure 1: Polymerization of Deoxygenated Red Blood Cells  
This figure shows the change from oxygenated red blood cells (red) to 
deoxygenated red blood cells (pink). The left side of the figure illustrates the 
hydrophobic interactions between the beta subunits of adjacent hemoglobin 
molecules depicted as projections and indentations in the cartoon and as blue 
and green sites on the grey beta subunits in the high-resolution model. The 
middle diagram shows the 14-strand fiber resulting from polymerization. The right 
side of the figure shows how the polymerization deforms the red blood cell into a 
sickle shape portrayed in a cartoon as well as in a scanning electron micrograph. 
Figure taken from (Bunn, 1997). 
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DISORDERS OF SICKLE CELL DISEASE 	
Those with SCD have at least one copy of the HbS mutation while the 
other beta-globin subunit of their hemoglobin can include a number of different 
mutations resulting in a large number of different genotypes. The most common 
genotype of SCD is when both beta-globin subunits contain HbS. This genotype 
is called sickle cell anemia and is the most severe variant out of all of the SCD 
disorders resulting in an overall lower survival rate by about 20 years. Three 
other common disorders of SCD are sickle cell hemoglobin C (HbSC), sickle-β0 
thalassemia (HbSβ0), and sickle-β+ thalassemia (HbSβ+) (Steinberg, 2009).  
 Sickle hemoglobin C (HbSC) is the second most frequent SCD disorder 
and results from the hemoglobin C (HbC) mutation. In the second beta globin 
chain the glutamic acid in the normal adult hemoglobin is replaced with lysine 
(Hannemann et al., 2011) and the resulting genotype contains 50% HbS and 
50% HbC (Lionnet et al., 2012). This disorder is generally less severe than HbSS 
and the complications associated with this condition present later in life 
compared to HbSS individuals. The presence of HbC in red blood cells increases 
the activity of the potassium-chloride cotransporter leading to the loss of both 
potassium and water from the cells and resulting in cell dehydration. This 
increases the concentration of hemoglobin in the red blood cells which enhances 
the sickling and polymerization of HbS (Nagel, Fabry, & Steinberg, 2003). The 
shape of HbSC cells also differ from those of HbSS cells with HbSC cells being 
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more folded than sickled, which is similar to the cells of HbC homozygotes 
(HbCC) (Lawrence, Fabry, & Nagel, 1991). 
 The two other less common disorders involve mutations in the beta 
thalassemia gene. In sickle-β0 thalassemia (HbSβ0), the beta globin chain is not 
produced so there is no normal hemoglobin present. In sickle-β+ thalassemia 
(HbSβ+), the beta globin chain is produced in reduced levels so small amounts of 
normal hemoglobin are present. With no production of HbA in HbSβ0 the 
symptoms and complications of this condition most resemble those of HbSS with 
both disorders being generally severe while HbSβ+ and HbSC have a less severe 
course of action (Serjeant, 2013). 
 In the Cooperative Study of Sickle Cell Disease (CSSCD), the largest 
study looking at both children and adults with SCD, individuals with HbSS and 
HbSβ0 had more bouts of pain and severe anemia compared to patients with 
HbSC and HbSβ+ (Platt et al., 1991). HbSS and HbSβ0 individuals also had more 
episodes of the pulmonary complication, acute chest syndrome (Castro et al., 
1994). One exception to the degree of severity seen in these four disorders of 
SCD is the higher prevalence of proliferative sickle retinopathy (PSR), which is 
the blockage of vessels and thus lack of oxygen leading to the peripheral retina 
(Goldberg, 1977), seen in HbSC and HbSβ+ individuals compared to HbSS and 
HbSβ0 individuals (Serjeant, 2013).  The exact reason for this is unknown but in 
HbSC it has been hypothesized that the cause of PSR is due to the higher 
hemoglobin concentration making the blood thicker (Steinberg, 2008). It has also 
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been hypothesized that the occurrence of PSR in HbSS is lower because the 
circulation to the retina becomes dysfunctional early on so the lesions 
characteristic of this complication are prevented from forming while the retinal 
circulation in HbSC is maintained allowing for the development of the lesions 
(Nagel et al., 2003). 
 
Populations Affected by Sickle Cell Disease 
Sickle cell disease mainly affects individuals of African, Hispanic, and 
Mediterranean origin as well as those from India and Saudi Arabia. According to 
the World Health Organization, about 275,000 SCD births occur every year in the 
world (World Health Assembly, 2006). Figure 2 shows the distribution of the HbS 
allele in the world. Individuals in sub-Saharan Africa are the most affected by 
SCD with more than 250,000 newborns with sickle cell anemia being born every 
year (Serjeant, 2013). These numbers have been hard to estimate because in 
many of these countries where SCD is thought to be most prevalent there are no 
universal newborn screening programs to allow for early diagnosis. 
Consequently, many children die from complications before being diagnosed or 
do not receive treatment early enough causing an underestimation of SCD 
individuals (Tshilolo et al., 2008). 
In the United States SCD affects 1 in 365 African-Americans and 1 in 
16,305 Hispanic Americans (Hamideh & Alvarez, 2013). It has been estimated 
that there are 72,000-98,000 individuals with SCD in the U.S. (Hassell, 2010). 
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Figure 2: Prevalence of HbS Allele Worldwide 
This figure shows the regions with HbS affected individuals. Also shown are the 
estimates of individuals affected by the 4 most common disorders of SCD every 
year in each region. Figure taken from (D. C. Rees, Williams, & Gladwin, 2010). 	
 
 
Diagnosis 
 The diagnosis of SCD in the United States is done through universal 
newborn screening. Within the first few months of birth the blood of infants is 
tested, most frequently by isoelectric focusing, which is a type of electrophoresis 
that separates hemoglobin on a gel (McGann, Nero, & Ware, 2013). Newborn 
screening was first suggested in the 1980’s after a trial looking at oral penicillin 
as a preventive measurement was shown to decrease the occurrence of 
pneumococcal sepsis during childhood. The early detection of children with sickle 
cell anemia allowed researchers to administer the pneumococcal vaccine sooner 
resulting in significant drop in death due to infection (Gaston et al., 1986). 
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 Although the benefit of newborn screening was shown and this form of 
diagnosis strongly recommended by the National Institutes of Health at their 
1987 Consensus Development Conference on Newborn Screening for Sickle Cell 
Disease and other Hemoglobinapathies, (National Institutes of Health, 1987) it 
was not until 2006 that newborn screening occurred throughout the entire United 
States (McGann et al., 2013). 
 
Survival and Mortality 
 Survival in those with SCD has come a long way in the past few decades. 
In the Dallas Newborn Cohort, survival at the age of 18 was 93.9% in HbSS and 
HbSβ0 and 98.4% in HbSC and HbSβ+ patients in 2010 compared to 85.6% and 
97.4% respectively in 2004. These increases in survival are due to many factors 
including newborn screening and the decrease in age at which vaccinations are 
given (Quinn, Rogers, McCavit, & Buchanan, 2010).  Figure 3 shows a significant 
decrease in death for the 1-4 age group resulting from these factors. The figure 
also shows that there was a shift in death age in adults from the 20-24 and 25-34 
age groups to the 35-44 and 45-54 age groups. Although more patients are 
surviving past adolescence there is still the issue of complications that occur in 
adulthood. These individuals are now surviving into their thirties (Hassell, 2010) 
and higher but they still have a shorter lifespan by about 30 years when 
compared to the general population (Hamideh & Alvarez, 2013).  
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Figure 3: Age at Death by Age Group 
This figure shows the number of  sickle cell disease deaths for each age group 
during 4 specific years. Figure taken from (Hassell, 2010) 
 
 
 In a study looking at mortality of SCD in the U.S. from 1999-2009 the 
mortality rate of males was 35-44 years while in females it was 45-54 years 
(Hamideh & Alvarez, 2013). Many deaths have unexplained causes but a few 
studies noted some trends. In the Dallas Newborn Cohort patients were at the 
highest risk of death during their transition from pediatric to adult care (Quinn et 
al., 2010). Cardiovascular and pulmonary conditions were other common causes 
of death. These included acute chest syndrome, pulmonary hypertension, and 
congestive heart failure (Hamideh & Alvarez, 2013).  
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General Complications 
Pain Crises 
Pain crises is the number one symptom of SCD resulting in 95% of 
hospital admissions (Ballas & Lusardi, 2005). Patients most commonly feel this 
pain in their hands, feet, back, stomach, chest, or head (Platt et al., 1991). It is 
caused by the blockage of the smaller vessels by red and white blood cells 
resulting in blood flow interference and thus a reduction in the transportation of 
oxygen to the organs and tissues of the body (Gladwin & Vichinsky, 2008). This 
obstruction of blood flow is what is known as vaso-occlusion.  
In the microcirculation, blood flow on the arteriolar side is much faster than 
on the venular side so as soon as the sickled red blood cells cross the capillaries 
and enter the venules they are travelling at a lower velocity until they reach the 
larger veins (Lipowsky, Kovalcheck, & Zweifach, 1978). Not only does this give 
the sickled cells ample time to start adhering to the endothelium of the vessels, it 
has also been shown that these cells are the most adherent in these post 
capillary venules unlike in the arterioles where the fast speed of blood flow 
prevents cell attachment (Lipowsky et al., 1978). The red blood cells have been 
categorized based on their density, which is determined by hemoglobin 
concentration. The increased density of these cells is due to cell dehydration 
caused by the increased activity of certain transporters that lead to removal of 
water from the cells (Joiner, 1993). From least to most dense there are 
reticulocytes, which are the immature red blood cells, discocytes, which are 
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young red blood cells, dense discocytes, and irreversible sickled cells (ISC’s). In 
the post capillary venules it is the least dense cells, the reticulocytes and 
discocytes, that adhere to the endothelium preventing the passage of the most 
dense cells, the dense discocytes and ISC’s, resulting in the blockage of the 
vessels (Figure 4) (Kaul, Fabry, & Nagel, 1989). 
 
 
Figure 4: The Manifestation of Vaso-Occlusion 
Shown is the two-step process that results in vaso-occlusion. .During the first 
initiation step, reticulocytes, one of the least dense cells, adhere to the 
endothelium. This leads to the second propagation step, where irreversibly 
sickled cells and discocytes, labeled here as biconcave discs, are unable to get 
past the attached reticulocytes and so begin to pile up behind them resulting in 
the blockage that is characteristic of vaso-occlusion. With red blood cells being 
held up in these vessels they start to take their sickled form. Figure taken from 
(Hebbel, 2000). 
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With this adhesiveness to the endothelium, blood flow through the veins is 
reduced further causing red blood cells to spend more time than usual in the 
deoxygenated state. This allows more cells to sickle and polymerize causing 
additional adherence to the endothelium and more blood flow obstruction 
(Ferrone, 2004). It is this blockage of the vessels that causes what is known as 
an acute painful episode (Hebbel, 2000) 
The reduced blood flow caused by vaso-occlusion leads to organ and 
tissue damage. Further damage results from reperfusion injury, repeated cycles 
of ischemia and reperfusion, leading to inflammation (Hebbel, Osarogiagbon, & 
Kaul, 2004).  When blood flow is inhibited it causes ischemia meaning oxygen is 
not reaching the tissues. This is remedied trough reperfusion, where the tissues 
become re-oxygenated.  This re-introduction of oxygen is the main cause of 
reperfusion injury (Carden & Granger, 2000). This process causes the production 
of reactive oxygen species and the expression of inflammatory mediators all 
leading to inflammation and vasculopathy (Hebbel et al., 2004). 
Hemolysis 
Hemolysis is the breakdown of red blood cells with the release of its 
components into the plasma. This breakdown is a result of sickle cell 
polymerization which makes the red cell membrane unstable and prone to 
premature rupture (Reiter et al., 2002). With SCD red blood cells are breaking 
down faster than they are being produced by the bone marrow resulting in lower 
concentrations of hemoglobin in the body. This causes anemia, which has its 
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own number of symptoms associated with it. Hemolysis, like vaso-occlusion, also 
leads to the dysfunction of endothelial cells, which occurs through the removal of 
nitric oxide by the hemoglobin released into the blood (Figure 5)(D. C. Rees et 
al., 2010).  
 
 
 
 
Figure 5: Mechanism of Hemolysis and Vaso-Occlusion 
Shown is a schematic of hemolysis and endothelial dysfunction. Figure taken 
from (Rees et al., 2010). 
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Nitric oxide is produced by endothelial cells and is released into smooth 
muscle cells and blood vessels where it causes vasodilation among its other 
functions (Moncada & Higgs, 1993). When nitric oxide encounters oxygenated 
hemoglobin in the blood it is broken down into methemglobin and nitrate ions. 
This reaction is normally limited because the red cell membrane acts as a barrier 
between nitric oxide and hemoglobin. Also, since oxygentaed hemoglobin is 
present on the arterial side of the circulation, the rapid flow of plasma along the 
endothelium acts as another barrier separating the nitric oxide in the endothelium 
from the red blood cells passing by in the blood vessels (Schechter & Gladwin, 
2003).  
During hemolysis hemoglobin is released into the plasma which removes 
both the red cell membrane barrier and the plasma barrier allowing nitric oxide to 
now interact with the hemoglobin and be converted into methemglobin and 
nitrate (Schechter & Gladwin, 2003). This removal of nitric oxide prevents it from 
having its vasodilation effect on the vasculature. Arginase is also released during 
hemolysis and acts by decreasing the levels of arginine, the substrate required 
for the synthesis of nitric oxide, resulting in even less nitric oxide being available 
(Gladwin & Vichinsky, 2008).  
Another function of nitric oxide is the inhibition of leukocyte adhesion to 
the endothelium of post-capillary venules (Kubes, Suzuki, & Granger, 1991). In 
SCD there is no inhibition because hemolysis removes nitric oxide so the 
activation of the endothelium results in the increased adherence of lymphocytes, 
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monocytes, and granulocytes through the expression of leukocyte adhesion 
molecules like VCAM-1 (vascular cell adhesion molecule-1) and E-selectin. It is 
this expression that causes the adherence of reticulocytes to the endothelium 
seen in vaso-occlusion (De Caterina et al., 1995). 
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Table 1: Major complications of Sickle Cell Disease  
Table lists the most common complications of SCD that occur as a result of vaso-
occlusion and hemolysis. Figure taken from (Steinberg, 1999). 
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Pulmonary Complications 	
Acute Chest Syndrome 
Acute chest syndrome (ACS) is the leading cause of death in SCD 
individuals and the second most common cause of hospitalization (Raphael, 
Kavanagh, Wang, Mueller, & Zuckerman, 2011). It has been defined as a density 
in the lung as seen on a chest x-ray. This pulmonary infiltrate in the alveolar 
spaces of the lungs usually involves at least one complete segment of a lung and 
presents with a number of symptoms including fever, chest pain, rapid breathing, 
wheezing, and/or cough (Vichinsky et al., 2000). 
Epidemiology  
 ACS occurs more in HbSS and HbSβ0 comapred to HbSC and HbSβ+ 
individuals with HbSS patients having the highest incidence overall (Castro et al., 
1994). Although common in adults ACS is more prevalent in children, with those 
between the ages of two and four having the highest incidence (Ballas et al., 
2010).  
Clinic Presentation 
The clinical features of ACS differ between children and adults with 
children presenting more with wheezing, cough and fever while adults present 
with pain in their extremities and shortness of breath (Vichinsky et al., 1997).   
The Copperative Study of Sickle Cell Disease showed that about 50% of patients 
diagnosed with ACS are already in the hospital for other complcations with pain 
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crises being the most common reason. In adults it usually takes 24 to 72 hours 
after the start of a pain crises to develop ACS with some signs of this 
development being a suuden drop in hemoglobin levels, an increase in hemolysis 
markers, and a decrease in platelet count (Gladwin & Vichinsky, 2008). 	
Etiology 
 Figure 6 shows how three major triggers associated with vaso-occlusion 
produce the cycle of ACS that can lead to lung injury and tissue death. In a study 
done by the National Acute Chest Syndrome Study Group (NACSSG) looking at 
538 patients with SCD, a specific cause of an ACS episode was determined in 
only 38% of patients (Vichinsky et al., 2000). Three major causes of ACS are 
pulmonary infection, lung obstruction by bone marrow fat, and accumulation of 
sickled red blood cells in the pulmonary vasculature (Gladwin & Vichinsky, 2008) 
Of these three causes pulmonary infection is the most common with Chlamydia 
pneumoniae and Mycoplasma pneumoniae being the most prevalent pathogens. 
In the NACSSG study pulmonary infection was the most common cause of ACS 
in children less than nine years of age (35%). The prevalence in children 10 to 19 
years of age was 22% and in adults older than 20 years of age it was 26% 
(Vichinsky et al., 2000). 
 Lung obstruction by bone marrow fat is due to pain crises specifically in 
the pelvis and femur. Fluid accumulation and obstruction of the bone marrow 
leads to necrosis causing its contents to be released into the blood which then 
reach the lungs resulting in inflammation, hypoxia, and pulmonary hypertension 
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(Gladwin & Rodgers, 2000). The third major cause of ACS is the accumulation of 
sickled red blood cells. The red cells that enter the lungs are already in the 
deoxygenated state and with hypoxia due to other complications like vaso-
occlusion there is increased HbS polymerization and thus sickling. This causes 
the adhesion of sickled cells to the endothelium of the pulmonary vessels 
resulting in blockages that ultimately lead to ACS and the death of lung tissue 
(Figure 6) (Graham, 2004).  
	 21	
 
 
 
Figure 6: Process of Acute Chest Syndrome 
The three major triggers associated with vaso-occlusion produce the cycle of 
ACS that can lead to lung injury and tissue death. Figure from (Gladwin & 
Vichinsky, 2008). 
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Treatments 
 
 The treatment of SCD depends on the severity of an individual’s condition. 
Most therpay is supportive, helping one deal with the pain and the complications 
associated with SCD, but they do not help treat the long term effects SCD has on 
the organs and tissues of the body (Sheth, Licursi, & Bhatia, 2013). The two 
forms of treatment commonly used to manage SCD are blood transfusion and 
hydroxyurea therapy. 
 Red blood cell transfusion was one of the earliest forms of therapy used in 
treating SCD. It works by increasing one’s hematocrit levels so that their blood is 
better able to carry oxygen to the tissues. In SCD patients this increase dilutes 
the blood so that the percentage of HbS is lower, resulting in less sickling and 
thus less SCD symptoms like anemia and vaso-occlusion (Wayne, Kevy, & 
Nathan, 1993). There are three types of transfusions used based the severity of 
one’s symptoms.  
Simple transfusion is used when a patient needs to increase the amount 
of oxygen getting to their tissue. The downside of this is the possible increase in 
the blood’s viscosity due to the increase in hematocrit, which can actually make it 
harder for oxygen to reach the tissues and result in pain crises. Chronic 
transfusion is used to lower the amount of HbS and increase the amount of 
normal adult hemoglobin HbA. Long term use has been shown to lead to 
complications so this type of transfusion is used only in specific situations like 
cerebrovascular disease (Russell et al., 1984). Exchange transfusion is used to 
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either prevent or help treat complications of SCD that are detrimental to the 
organs (Wayne et al., 1993). 
Hydroxyurea was originally used in the 1980’s as a chemotherapeutic 
agent but is now one of the most important drugs used in treating SCD because 
of its ability to increase fetal hemoglbin (HbF) (A. L. Rees, 2015). It works by 
preventing the aggregation of HbS molecules in the blood, decreasing the 
sickling of red blood cells and resulting in less painful episodes as well as the 
need for transfusions as seein in the BABY HUG trial (Wang et al., 2011). This 
drug was originally used only in adults and is approved by the FDA for only 
adults but is increasingly being used in children with positive results. 
Because the symptoms of SCD are so variable individuals use different 
dosages of hydroxyurea and have different HbF responses. Figure 7 shows the 
comparison of 2 children with HbSS who received hydroxyurea. Both children 
were given increased doses until they reached their maximum tolerated dose. 
Although they both had different HbF responses they still showed improvement in 
their bloodwork over time (Ware, 2010). 
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Figure 7: Morphologic Changes During Increased Hydroxyurea Dosage 
Shown are the differences in HbF response between two children when given 
increased doses of hydroxyurea. (A-C) show the change of the child with a high 
HbF response and (D-F) show the child with a low HbF response. They both 
show an increase in hemoglobin and volume of red blood cells as well as a 
decrease in sickled cells, white blood cells, and neutrophils. Figure taken from 
(Ware, 2010). 
  
 
  
 
PULMONARY ARTERIAL HYPERTENSION 
History  
Before the 1950’s not much was known about pulmonary hypertension 
due to the lack of techniques used to study the heart and lungs. In 1940  
Cournand and Richards developed the technique of cardiac catheterization after 
seeing German physician Werner Forssmann perform it on himself in 1929 
(Cournand et al., 1945). These two physicians first studied this technique on 
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different animals and then used it on humans. The use of right heart 
catheterization allowed physicians to take blood samples, measure blood 
pressure in various parts of the heart, and measure gas concentrations in the 
blood. 
In 1951 Dresdale who had worked under Cournand and Richards, looked 
at pulmonary hypertension in a mother and her two children. He was unable to 
determine the cause of their condition giving it the name primary pulmonary 
hypertension, which is today known as idiopathic pulmonary hypertension 
(Dresdale, Schultz, & Michtom, 1951). In 1958 Heath and Edwards looked at the 
structural changes in the pulmonary arteries in patients with pulmonary 
hypertension associated with congenital septal defects of the heart. With this 
information they categorized these changes into six grades (Heath & Edwards, 
1958). In 1970 Wagenvoort and Wagenvoort gave a full description of primary 
pulmonary hypertension by looking at 156 patients in Europe (Wagenvoort & 
Wagenvoort, 1970). 
In 1973 the WHO held its first meeting in Geneva, Switzerland where 
pulmonary hypertension was classified into two groups, pulmonary and 
secondary pulmonary hypertension (WHO Meeting on Primary Pulmonary 
Hypertension, Hatano, & Strasser, 1975). 
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Pathogenesis 
Pulmonary arterial hypertension (PAH) is high blood pressure in the 
arteries of the lungs [CITE]. It mostly affects the small arteries of the lungs which 
are called the resistance arteries (McLaughlin et al., 2009). These arteries carry 
blood from the heart to the lungs and control their flow. In this disorder the 
resistance arteries become constricted so that less blood is flowing through them 
and thus reduced blood is reaching the lungs (Chaudry et al., 2011). This causes 
an increase in the resistance of the arteries and in order to overcome this there 
has to be an increase in pressure so that enough blood still reaches the lungs. 
This is done by the right side of the heart, specifically the right ventricle. With the 
right side of the heart having to work much harder to pump blood through the 
resistance arteries it eventually becomes weakened and results in right heart 
failure (McLaughlin et al., 2009).  
In normal vessels there is a balance between cell proliferation and 
apoptosis so that the vascular luminal cross-section doesn’t change allowing 
blood to flow through the vessels at a constant rate. In PAH there is an increase 
in the protein thromboxane A2 in the smooth muscle cells of the resistance 
arteries and a decrease in prostacyclin production. Thromboxane A2 is a 
hormone known for being a vasoconstrictor and it also causes cell growth and 
promotes blood clotting. Prostacyclin is a compound that causes vasodilation. So 
with the vasoconstriction and cell proliferation caused by thromboxane A2 and 
the inhibition of vasodilation normally caused by prostacyclin there is an overall 
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decrease in the diameter of the arteries. Endothelin-1 is another protein that is 
increased in PAH and with its vasoconstriction and cell proliferation properties it 
also contributes to the narrowed vessels resulting in the need for higher 
pressures (McLaughlin et al., 2009). 
 
Diagnosis 
The diagnosis of PAH is determined by looking at certain measurements 
using Doppler echocardiography and right heart catheterization. It has been 
shown that right heart catheterization is more accurate than Doppler 
echocardiography and should be used for the confirmation of PAH (McLaughlin 
et al., 2009). Doppler echocardiography is less invasive as it is a type of 
ultrasound of the heart showing the movement of blood. It is used on patients 
who are suspected of having PAH and it can be used to determine mean 
pulmonary arterial pressure (mPAP), left arterial pressure (LAP), and cardiac 
output (CO) all of which are done by measuring tricuspid regurgitant velocity 
(TRV). These measurements also allow for the calculation of pulmonary vascular 
resistance (PVR) (D’Alto et al., 2013). Right heart catheterization is more 
invasive allowing for a more accurate measurement of the pressures in the 
pulmonary arteries. In this procedure a catheter is put into the right side of the 
heart and then into the pulmonary artery [CITE]. Measurements of cardiac 
output, pulmonary capillary wedge pressure, and mPAP (McLaughlin et al., 
2009). 
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With the use of both of these procedures it has been determined that PAH 
is confirmed in individuals having a mPAP ≥ 25 mmHg, pulmonary capillary 
wedge pressure ≤ 15 mmHg, and a PVR > 3 Wood units (Chin & Rubin, 2008). 
The measurement of TRV done during Doppler echocardiography is used to 
determine the suspicion of PAH in an individual. More testing is done in those 
who have a TRV > 2.5 m/sec which corresponds to a mPAP of 30 mmHg 
(Dahoui et al., 2010) 
 
Classifications 
Pulmonary hypertension used to be categorized into two groups, primary 
and secondary pulmonary hypertension but in 1998 the second World 
Symposium took place in France and pulmonary hypertension was classified as 
having 5 major categories which have been modified over the years (Table 2). 
Group 1 is labeled as pulmonary arterial hypertension and involves conditions 
where pulmonary hypertension is concentrated in the pulmonary arteries. In this 
group idiopathic and hereditary PAH occur more in females compared to males 
(Thenappan, Shah, Rich, & Gomberg-Maitland, 2007). A major cause of heritable 
PAH seems to be a mutation in the bone morphogenetic protein receptor type 2, 
which is found in 80% of cases. Drugs and toxins like appetite suppressants and 
stimulating medications have also been found to cause PAH. Among the 
conditions associated with PAH connective tissue disease is the most severe 
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while portal hypertension and congenital heart disease are the least severe. 
(Chin & Rubin, 2008). 
 Group 2 involves pulmonary hypertension with left heart disease also 
known as pulmonary venous hypertension. Group 3 is associated with lung 
disease and/or hypoxemia. Within this group pulmonary hypertension is a 
frequent complication with these conditions and although not extremely severe 
individuals do have low survival rates. Group 4 is chronic thromboembolic 
pulmonary hypertension caused by blockage of pulmonary vessels that have not 
been cleared and resulting in right ventricle dysfunction. Group 5 is pulmonary 
hypertension with uncertain multifactorial mechanisms and is where sickle cell 
disorder is classified (Chin & Rubin, 2008) (Simonneau et al., 2013). 
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Table 2: Pulmonary Hypertension Classifications. 
Shown are the 5 current major categories of pulmonary hypertension. Table 
taken from (Simonneau et al., 2013). 
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The WHO has also classified pulmonary hypertension into 4 functional 
categories used to assign disease severity. Functional class I describes 
individuals with no symptoms of pulmonary hypertension during rest, normal 
activities, or exercise. Functional class II individuals show no symptoms at rest 
but have a little trouble with normal activities and exercise. Functional class III 
individuals may be fine at rest but any type of activity will cause symptoms 
including shortness of breath and chest pain. Functional class IV is the most 
severe with individuals showing symptoms at rest. They have difficulty with any 
type of basic activity and show signs of right heart failure (WHO Meeting on 
Primary Pulmonary Hypertension, 1975). 
 
Right Heart Failure 
 Right heart failure is the main cause of death in individuals with PAH 
(D’Alonzo et al., 1991). Many factors play a role in this condition and a lot is still 
unknown but it all starts with the dysfunction of the right ventricle. When the 
resistance in the pulmonary arteries first increases less blood is able to flow 
through these vessels, resulting in increased amount of blood left in the right 
ventricle. The right ventricle then compensates for this increased afterload by 
increasing its contractility , which over time leads to right ventricle hypertrophy 
where the cardiac muscle of this chamber becomes thickened as a result of 
working harder than normal. In a study looking at 578 patients belonging to 
Group 1 of the World Health Organization (WHO) classification, 55% of patients 
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had right ventricular hypertrophy and 22% had right atrial enlargement 
(Thenappan et al., 2007).  
This increase in size of the heart chambers is due to an increased 
afterload. Because of the higher resistance in the pulmonary arteries less blood 
is flowing through from the heart to the lungs so there is more blood left over in 
the right ventricle causing the right side to increase it’s size to compensate for 
the extra volume of blood (McLaughlin et al., 2009). As the increased pulmonary 
resistance persists the right ventricle becomes less able to compensate leading 
to dilation of the ventricular walls and no further increase in contractility. This 
causes less blood to flow through the pulmonary vessels and into the left side of 
the heart resulting in a lower cardiac output that can ultimately lead to right heart 
failure (Noordegraaf & Galiè, 2011). 
 
Treatments 
 The treatment of pulmonary hypertension depends on the severity of the 
disease. The earlier one is diagnosed the better the results of treatment. There 
are two types of treatment, primary and advanced. Primary therapy is used at the 
beginning stages of pulmonary hypertension and focuses on treating the causes 
of the pulmonary hypertension. Advanced therapy is used with severe disease 
and focuses on treating the actual pulmonary hypertension. Figure 7 shows the 
process used when treating pulmonary hypertension (McLaughlin et al., 2009). 
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Figure 8: Procedure Used To Treat Pulmonary Hypertension.  
Shown are the primary and advanced treatments of pulmonary hypertension. 
Primary treatments include anticoagulants, diuretics, oxygen, and digoxin. 
Advanced treatments depend on acute vasoreactivity testing and include calcium 
channel blockers (CCBs) for a positive response and endothelin receptor 
antagonists, phosphodiesterase type-5 inhibitors and prostanoids for a negative 
response. Figure taken from (McLaughlin et al., 2009) 
 
Primary treatment can be used on individuals with pulmonary 
hypertension in any of the five WHO groups. It includes anticoagulants, diuretics, 
oxygen, and digoxin (Figure 7). Warfarin is the anticoagulant commonly used and 
it works by preventing the formation of blood clots that would otherwise block 
blood flow in the vessels. This is most beneficial for idiopathic PAH and group 4 
PH individuals who are prone to thrombosis. Diuretics are used to reduce fluid 
build up caused by the increased afterload that occurs in right heart failure (Chin 
	 34	
& Rubin, 2008). Desaturation occurs with vasoconstriction of the pulmonary 
arteries due to hypoxemia resulting from low cardiac output (Humbert, Sitbon, & 
Simonneau, 2004). This is treated with supplemental oxygen, which keeps an 
individual’s oxygen saturation above 90% (McLaughlin & McGoon, 2006). The 
use of digoxin till needs to be investigated further but so far it has been shown to 
help the heart pump more blood thus increasing its cardiac output which is useful 
in individuals with right heart failure (McLaughlin et al., 2009).  
 Advanced Therapy in WHO groups 2-5 has not been researched as much 
as group 1, specifically idiopathic PH so the following treatments are based on 
studies done with group 1 PAH. Treatment starts with acute vasoreactivity 
testing, which is done during right heart catheterization and is a sign of how well 
an individual will respond to calcium channel blockers. The patient is given either 
inhaled nitric oxide, intravenous prostacyclin, or intravenous adenosine, which 
are all vasodilators (Humbert et al., 2004). A positive response is indicated by a 
mPAP that falls by at least 10 mmHg and is less than or equal to 40 mmHg with 
no decrease in cardiac output (McLaughlin et al., 2009). Less than 10% of 
individuals with idiopathic PAH have a positive vasoreactivity test (Sitbon et al., 
2005). The most common calcium channel blockers are nifedipine, diltaizem, and 
amlodipine and the choice of which one to use is determined by the individual’s 
baseline heart rate (Galiè et al., 2009). Patients taking these drugs must be 
followed closely because only half of them continue to respond long term 
(sustained response) (Chin & Rubin, 2008). Also a lack of improvement into 
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WHO functional class I or II indicates that this treatment won’t work long term so 
other forms of therapy should be considered (McLaughlin et al., 2009). 
 Patients with a negative acute vasoreactivity response are then classified 
as being high risk or low risk. One’s risk level is determined by a combination of 
factors including signs of right heart failure, severity of symptoms, and WHO 
functional class (McLaughlin et al., 2009). Regardless the risk level the three 
types of treatment given are endothelin receptor antagonists, phosphodiesterase 
type-5 inhibitors, and prostanoids. The endothelin receptor antagonists used are 
bosentan, ambrisentan and sitaxsentan. They act by inhibiting endothelin-1, 
which is a vasoconstrictor of the vessels (Chin & Rubin, 2008). The 
phosphodiesterase type-5 inhibitors, sildenafil and tadalafil, act by preventing the 
fast breakdown of cyclic GMP by phosphodiesterases therefore resulting in 
vasodilation by nitric oxide (McLaughlin et al., 2009). The prostanoids are 
epoprostenol, treprostinil, and iloprost. They are synthetic prostacyclin and act by 
inducing vasodilation and inhibiting platelet aggregation (Galiè et al., 2009). 
Epoprostenol has a very short half life so it must be given through a continuous 
pump while treprostinil and iloprost are longer acting (Chin & Rubin, 2008). 
 Some patients continue to get worse while being treated with one of the 
above-mentioned medications or their condition is too severe to be treated with 
just one drug (monotheraphy) so they require combination therapy. This involves 
the use of more than one drug taken at the same time and seems to be safe and 
effective. The best combination of drugs has not yet been determined so the 
	 36	
choice of therapy should be based on each individual’s characteristics (Buckley, 
Staib, & Wicks, 2013). 
Lastly if medical therapy is unsuccessful in improving conditions the last 
consideration is lung transplantation and atrial septostomy. Lung transplantation 
can be a single or double transplantation and has been shown to improve quality 
of life. Atrial septostomy is when a shunt in created between the left and right 
heart atria decreasing the pressure on the right side of the heart (McLaughlin et 
al., 2009). 
 
PULMONARY ARTERIAL HYPERTENSION IN SICKLE CELL DISEASE 
 
Prevalence and Mortality 
 The prevalence of adults with sickle cell disease associated with 
pulmonary hypertension differs between studies and countries. Most researchers 
have used Doppler echocardiography to diagnose pulmonary hypertension, 
looking for a TRV of 2.5 m/sec or greater. One study in the United States found 
pulmonary hypertension in 36% of patients with HbSS and HbSβ0 and in 25% of 
patients with HbSC, HbSβ+, and in the less common sickle cell-hemoglobin 0 
Arab disease (SOArab) (De Castro, Jonassaint, Graham, Ashley-Koch, & Telen, 
2008). A study in Saudi Arabia found 37.1% of SCD adults to have pulmonary 
hypertension (Al-Khoufi, 2013). In children in the U.S. 30% with SCD had and 
elevated mPAP (Pashankar, Carbonella, Bazzy-Asaad, & Friedman, 2008) while 
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44% of children in London with HbSS and 6% with HbSC had pulmonary 
hypertension. 
 Other studies have used both echocardiography and right heart 
catheterization to look at pulmonary hypertension. In France 27% of adults with 
SCD had a TRV of at least 2.5 m/sec but on RHC the prevalence decreased to 
6% (Parent et al., 2011). In Brazil 40% of adults had pulmonary hypertension on 
echocardiography but only 10% were confirmed on RHC (Fonseca et al., 2012). 
Because echocardiography can inaccurately estimate the prevalence of 
pulmonary hypertension through imprecise measurement of mPAP it is now 
mostly used as a screening tool to see which patients are at risk of having 
pulmonary hypertension (McGoon et al., 2004). 
Patients with both pulmonary hypertension and sickle cell disease have 
higher hemodynamic measurements compared to SCD individuals without 
pulmonary hypertension. Although these values are not as high as in individuals 
with just idiopathic pulmonary hypertension the association between these 2 
conditions results in a significant increase in mortality (Gladwin et al., 2004). 
Figure 8 shows the rise in mortality of SCD individuals with pulmonary 
hypertension in the months after diagnosis compared to SCD individuals without 
pulmonary hypertension. Their survival is inversely proportional to their tricuspid 
regurgitant jet velocity (TRV), which is used to estimate mean arterial pressure 
(mPAP). A TRV of less than 2.5 m/sec corresponds to a normal mPAP while a 
TRV of 2.5 m/sec or greater corresponds to a high mPAP. Those with an 
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increasing mPAP show a continual increase in mortality rate as time goes on 
(Gladwin et al., 2004).  
 
  
 
Figure 9: Estimated Survival of SCD Individuals With and Without 
Pulmonary Hypertension 
This figure compares survival rate of sickle cell disease individuals without 
diagnosed pulmonary hypertension (dashed line) and those with diagnosed 
pulmonary hypertension (solid line). Figure taken from (Gladwin et al., 2004). 
 
 
Pathogenesis 
 The pathogenesis of pulmonary hypertension in sickle cell disease has not 
been fully established but there are many theories that have been studied. Three 
commonly proposed theories are decreased nitric oxide availability due to 
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hemolysis, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, and 
lactate dehydrogenase (LDH) as a biomarker. As previously mentioned in 
process of hemolysis, the breakdown of red blood cells in SCD patients causes a 
decreases in NO levels because released hemoglobin binds with nitric oxide and 
released arginase increases its levels in the plasma shifting its metabolism from 
producing arginine to producing ornithine thus decreasing the amount of arginine 
that can be used to make NO (Gladwin & Vichinsky, 2008). One study found that 
increased levels of arginase in the plasma correlated with patients who had 
pulmonary hypertension and the lower the levels of arginine in a patient’s plasma 
the more severe their pulmonary hypertension. So the endothelial dysfunction 
due to low levels of NO and the increased amount of ornithine due to higher 
levels of arginase in the plasma are thought to contribute to the pathogenesis of 
pulmonary hypertension (Morris CR, Kato GJ, Poljakovic M, & et al, 2005).  
Another study looked at N-terminal pro-brain natriuretic peptide (NT-
proBNP) levels in patients from both the National Institute of Health’s Pulmonary 
Hypertension Screening Study and the Multicenter Study of Hydroxyurea in 
Sickle Cell Anemia Patients’ Follow-up Study. Researchers found that high NT-
proBNP levels were due to right ventricular dysfunction, which leads to 
pulmonary hypertension. It was also shown that these biomarkers levels were 
also correlated with tricuspid regurgitant jet velocity whose measurement is a 
sign of possible pulmonary hypertension. Lastly an association between LDH and 
hemolysis was found in studies of both adults and children. In one study of adult 
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SCD patients LDH was found to be associated with several sign of hemolysis 
including low levels of hemoglobin and high levels of plasma arginase (Kato et 
al., 2006). In a study with children, although LDH wasn’t being studied as a 
biomarker for hemolysis it was found to be the strongly correlated with an 
increased TRV which correlated with signs of hemolysis (Liem, Young, & 
Thompson, 2007). When LDH was correlated directly to hemolysis in the study it 
was found to only explain 30% of the elevated TRV suggesting that there are 
possibly more than just one cause of pulmonary hypertension in the pediatric 
population.  One suggested theory is hemolytic anemia causing the release of 
plasma free hemoglobin, which reacts with nitric oxide decreasing its 
bioavailability. Arginase present in the red cells also reduces the bioavailability of 
nitric oxide and together. 
 
FUTURE ENDEAVORS.  	
 The study of pulmonary hypertension in children with sickle cell disease 
has only recently come to be researched; thus there are many unknowns. The 
biggest hindrance in the development of defined management of pulmonary 
hypertension in this population is the unknown cause of the disease itself.. As 
previously mentioned there are several proposed theories currently being studied 
and it looks like there will probably be more than just one cause suggesting the 
need for more than just one form of treatment. Right now the research indicates 
that the next step should be performing more longitudinal studies with a high 
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number of subjects who are just children and young adults. Once more clinical 
trials on this age population are completed and the specific causes of pulmonary 
hypertension are determined, a specific treatment plan can be put into place and 
patients, both children and adult SCD patients, can begin to avoid the increased 
mortality associated with having pulmonary hypertension. 
In the meantime, as more data is being attained about this condition in 
both children and young adults, there are actions that can be taken right now to 
help the pediatric population. Studies looking at the differences between children 
and adults have shown that an elevated TRV, which seems to be a prominent 
marker for pulmonary hypertension, does not have the same detrimental effects 
in children as it does in adults (Hagar, Michlitsch, Gardner, Vichinsky, & Morris, 
2008). This suggests that early intervention at a young age could either help 
prevent development of pulmonary hypertension or help reverse the effects of 
newly diagnosed pulmonary hypertension. 
Based on what is known today the TRV measurement is currently the best 
way to screen for possible pulmonary hypertension so children should be 
continuously tested so that pulmonary hypertension can be detected early and 
the appropriate measures can be take to avoid further complications. Figure 9 is 
a proposed algorithm for the testing of pulmonary hypertension. Doppler 
echocardiography should be the first screening tool to assess TRV 
measurements since it is not an invasive procedure. Those with a low TRV are at 
the lowest risk of developing PH but should still continue to get screened on a 
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regular basis. Those with acute TRV levels should frequently get screened and a 
treatment plan should be put in place to help lower their TRV levels so that they 
can avoid developing the symptoms of PH that will lead them to having to 
undergo right heart catheterization. Those with a high TRV should immediately 
be tested using the more invasive right heart catheterization to confirm if they 
truly have PH and if so what type. This will help determine the form of treatment 
needed. 
 
Figure 10: A Suggested Process of Assessing Pulmonary Hypertension in 
those with Sickle Cell Disease 
Shown is a proposed mechanism for the continual testing of pulmonary 
hypertension depending on one’s TRV levels based non-invasive Doppler 
echocardiography. Figure taken from (Klings et al., 2014) 
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In conclusion, there are still many questions to be answered about 
pulmonary hypertension in the young SCD population and more longitudinal 
studies are needed to determine the specific causes of PH and the best way to 
treat it. Early intervention for all children and young adults with SCD to avoid 
future complications is the best plan. There need to be more centers with 
physicians who are fluent in this condition so that children are being fully 
monitored and treated. This is the best way to keep a patient’s condition under 
control and help prevent pulmonary hypertension as well as other complications 
associated with SCD.  
Specific areas that should be studied more in the near future include 
specific treatment plans in this pediatric population as well as elevated TRV 
measurements and its effects on mortality risk. Once the direct association of 
TRV with pulmonary hypertension and its effects on children is determined it will 
become easier to come up with a management plan that will decrease the 
complications associated with pulmonary hypertension and hopefully 
substantially decrease mortality risk. 
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